

## SUPPLEMENTARY MATERIAL

Table 1. Reagents and concentrations used for skin and patch tests

Reagent	Concentration
Bencylpenicilloyl Octa-L-Lysine (BP-OL)	0.04 mg/mL
Sodium Benzylpenycilloate (DM)	0.50 mg/mL
Benzylpenicillin	10,000 IU/mL
Amoxicillin	20 mg/mL
Amoxicillin + clavulanic acid	20 mg/mL + 2 mg/mL
Cefuroxime	2 mg/mL
Meropenem	1 mg/mL
Clavulanic acid	1 mg/mL

Table 2. Raw data of the study medication consumption costs provided by the Hospital Pharmacy Service.

ACTIVE PRINCIPLE	SPECIALTY	COST (€)
Amoxicillin	Amoxicillin 500 mg, caps	-0.05
Amoxicillin	Amoxicillin 1g, sachets	15.94
Amoxicillin	Amoxicillin 250 mg/5 mL, suspension	10.49
Amoxicillin	Amoxicillin 250 mg, sachets	0.21
Amoxicillin	Amoxicillin 1g, vial	57.65
Ampicillin	Gobemicina <sup>®</sup> 500 mg, vial	1.09
Ampicillin	Gobemicina <sup>®</sup> 1000 mg, vial	1.21
Ampicillin	Britapen <sup>®</sup> 500 mg, caps	0.83
Benzylpenicillin	Penibiot <sup>®</sup> 1 million IU, vial	42.26
Penicillin combinations	Benzetacil <sup>®</sup> 6.3.3, vial	2.33
Phenoxymethylpenicillin	Penilevel <sup>®</sup> 250 mg, sachets	47.36
Cloxacillin	Anaclosil <sup>®</sup> 500 mg, caps	1.94
Cloxacillin	Cloxacillin 1g Normon <sup>®</sup> , vial	9.49
Cloxacillin	Cloxacillin 500 mg Normon <sup>®</sup> , vial	1.42
Amoxicillin/ clavulanic acid	Amoxicillin/ clavulanic acid 875 mg/125 mg, sachets	28.57
Amoxicillin/ clavulanic acid	Amoxicillin/ clavulanic acid 250 mg/62.5 mg, sachets	1.97
Amoxicillin/ clavulanic acid	Amoxicillin/ clavulanic acid 500 mg/125 mg, tablets	0.11
Amoxicillin/ clavulanic acid	Amoxicillin/ clavulanic acid 1g /100 mg, vial	79.08
Amoxicillin/ clavulanic acid	Augmentine <sup>®</sup> 100 mg/ 12.5 mg, suspension	16.64
Piperacillin/ tazobactam	Piperacillin/ tazobactam 2g /250 mg, vial	28.27
Piperacillin/ tazobactam	Piperacillin/ tazobactam 4g /500 mg, vial	23.35
Cefazolin	Cefazolin 1g Normon <sup>®</sup> , vial	7.95
Cefuroxime	Cefuroxime 750 mg, vial	49.97
Cefuroxime	Cefuroxime 500 mg, tablets	56.25
Cefuroxime	Zinnat <sup>®</sup> 250 mg/5 mL, suspension	11.80
Cefditoren	Spectracef <sup>®</sup> 200 mg, tablets	5.58
Cefditoren	Spectracef <sup>®</sup> 400 mg, tablets	2.78
Cefotaxime	Cefotaxime 1g,vial	7.12
Ceftazidime	Ceftazidime 1g, vial	12.44
Ceftriaxone	Ceftriaxone 1g, vial	13.15
Cefepime	Cefepime 1g, vial	2.29
Aztreonam	Azactam <sup>®</sup> 1g, vial	16.80
Ertapenem	Invanz <sup>®</sup> 1g, vial	74.77
Meropenem	Meropenem 1, vial	303.10
Meropenem	Meropenem 500 mg, vial	9.92
TOTAL		944.07

Proportion of adults: 296/336. Adults medication consumption costs: (296/336)\*944.07 = 831.68€

Table 3. Variables and data collected in the structured questionnaire

1. Sex	26. Assessment of visits to the Emergency Service
2. Age	27. Assessment of visits to the Health Center
3. First-degree family history of drug allergy	28. Treatment with antihistamines
4. First-degree family history of atopy	29. Treatment with corticosteroids
5. Personal history of atopy	30. Treatment with epinephrine
6. Personal history of drug allergy	31. Hospital admissions due to suspected drug allergy
7. Personal history of chronic disease	32. Number of days of hospitalization
8. Personal history of other diseases	33. Previous tolerance of the drug involved
9. Number of drugs regularly consumed	34. Consultations from the drug induced allergic episode
10. Drugs regularly consumed	35. Previous treatments
11. Treatment with beta-blockers	36. Number of visits to the physician in the Allergy Service
12. Treatment with ACE inhibitors	37. Number of visits to Nurse in the Allergy Service
13. Treatment with other drugs	38. Consultation in Allergy Service
14. Clinical Service that sent the patient	39. Treatments in Allergy Service
15. Reason for consultation	40. Skin prick test with aeroallergens
16. Indication for drug administration	41. Skin prick test with the involved drugs
17. Number of drugs involved in the reaction	42. Intradermal skin test with the involved drugs
18. Drugs involved in the reaction	43. Patch testing with the involved drugs
19. Route of administration	44. Total IgE
20. Number of doses administered	45. Specific IgE
21. Latency period until the onset of symptoms	46. Controlled exposure tests
22. Clinic Reaction	47. Result of controlled exposure tests
23. Duration of symptoms	48. Leaving the study
24. Number of episodes	49. Do you work for hire?
25. Number of visits to the Emergency Service	50. Hours of work lost for allergy diagnostic procedures

Table 4. Data of consumption (material and infrastructures)

MATERIAL	Total amount in 2017 (€)
Repairs, maintenance and conservation	1,771.69
Non inventoriable ordinary office material	152.44
Reprography and print material	701.23
Clothing	151.81
Supply of machinery spare parts	523.96
Lab's material	27,270.00
Generic healing material	403.05
General sanitary material	18,060.35
Cannules and tubes	172.15
Kitchen and dinette utensils	34.97
Cleaning	367.62
Non inventoriable ordinary office material	83.88
Electrical, electrical and communication material	138.67
Chemical products for laboratories	28.87
Kitchen and dinette utensils	23.52
Transportation cleaning	52.39
Total consumption transportation	42.35
<b>TOTAL CONSUMPTION</b>	<b>49,978.95</b>

Total number of visits to Allergy Service: 25,239

Number of patients that consulted for suspected beta-lactam allergy (older than 13) visits: 714

**Consumption (material and infrastructures):**  $(714/25,239) \times 22,507.93 = 1,413.88 \text{ €}$

Table 5. Payroll of the Allergy Service personnel

CONCEPT	Total amount in 2017 (€)
Payroll of personnel	541,958.69
Insurance of personnel	136,763.94
<b>TOTAL</b>	<b>678,722.63</b>

Total number of visits to Allergy Service: 25,239

Number of patients that consulted for suspected beta-lactam allergy (older than 13) visits: 714

**Payroll** :  $(714/25239) * 678,722.63 = 19,200.76€$

Table 6. Consumption and payroll of the personal proportionally to the number of patients/visits

	Allergy Service		Patients of the study	
	Total cost (€)	n° visits	n° visits	Total cost (€)
	(y)	(N)	(n)	(x)
Consumption	49,978.95	25,239	714	1,413.88
Personnel	678,722.63			19,200.76
TOTAL				20,614.64

The equation for attributing the total consumption and personnel costs to the patients of the study was:

$$x = \frac{y}{N} * n$$

Where:  $x$ : costs attributed to the patients of the study

$y$ : total costs attributed to all patients attended in the Allergy Service

$N$ : number of visits of all patients who were attended in the Allergy Service

$n$ : number of visits of the patients of the study

Table 7. Study population demographic characteristics.

<b>Total Patients (n=296)</b>		
Gender	Male (%)	102 (34.46)
	Female (%)	194 (65.54)
Age (years)	Range	14-91
	Mean (SD)	52.00 (20.39)
	Median (IQR)	55 (33)